Lobe Sciences Ltd. Announces That The Drug Enforcement Administration Has Issued The Initial 2023 Quota Allowing Export Of L-130
Yahoo FinanceMar 22, 2023 09:08 ET
Lobe Sciences Ltd. Announces Exclusive Collaboration With Quality Chemical Laboratories LLC
Quality Chemical Laboratories LLC ("QCL") has developed a synthetic pathway for psilocybin, psilocin and psilocin analogues exclusively for Lobe SciencesQCL agrees to supply Lobe Sciences research and
newsfileFeb 21, 2023 08:31 ET
Lobe Sciences Ltd (LOBEF) Increases Its Portfolio With Several New Chemical Entities (NCEs)
AB Digital, Inc.Jan 19, 2023 06:10 ET
Lobe Sciences Ltd. Announces Regulatory and Clinical Development Plans For 2022 and Early 2023
Vancouver, British Columbia--(Newsfile Corp. - July 7, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biotechnology company committed to discovering and de
newsfileJul 7, 2022 10:30 ET
Lobe Sciences Ltd. and Clearway Global LLC Enter into a Development Agreement to Manage Lobe Sciences Ltd.'s Global Regulatory and Development Strategy and its Implementation
Vancouver, British Columbia--(Newsfile Corp. - June 21, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biopsychedelics company committed to discovering and
newsfileJun 21, 2022 09:20 ET
CSE Bulletin: Consolidation - Lobe Sciences Ltd. (LOBE)
Toronto, Ontario--(Newsfile Corp. - Le 9 juin/June 2022) - Lobe Sciences Ltd. (the "Issuer") has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-cons
newsfileJun 9, 2022 15:05 ET
Lobe Sciences Ltd Announces Change in Record Date of Share Consolidation
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") announces that further to the Company's June 6, 2022, news releas
newsfileJun 9, 2022 10:35 ET
New Share Consolidation of Lobe Sciences Ltd., Here's What Changes
Lobe Sciences Ltd. (OTCQB:LOBEF), the Vancouver-based life sciences company focused on developing transformational psychedelic medicines through drug R&A, recently announced the implementation of
Benzinga Real-time NewsJun 8, 2022 14:36 ET
Lobe Sciences Ltd. to Webcast Live at VirtualInvestorConferences.com April 27th
Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.comVANCOUVER, British Columbia, A
Yahoo FinanceApr 25, 2022 08:52 ET
Lobe Sciences Ltd. to Participate in the Lytham Partners Spring 2022 Investor Conference
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") announced today that it will be participating in the Lytham Par
newsfileMar 30, 2022 08:24 ET
Lobe Sciences Ltd. to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest on March 28th - 30th from 9:00 A.M. - 5:00 P.M. EDT
Vancouver, British Columbia--(Newsfile Corp. - March 23, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") announced today that Philip Young, CEO, has been invited to pr
newsfileMar 23, 2022 10:00 ET
Lobe Sciences Ltd Invites You to Join Us at the Q1 Virtual Investor Summit
Vancouver, British Columbia--(Newsfile Corp. - February 22, 2022) - Lobe Sciences Ltd (CSE: LOBE) (OTCQB: LOBEF) today announced that Philip Young CEO will be attending the Q1 Virtual Investor Summit.
newsfileFeb 22, 2022 07:40 ET
No Data
No Data